However, the antiproliferative activity of 1 on ERα-positive MCF-7 breast cancer cells was 4-fold higher than for tamoxifen (EC50 ≈ 16 μM) and comparable to that of vorinostat (EC50 ≈ 4 μM for both compounds). Here, ESR1 is linked to breast carcinoma.